BANK VONTOBEL/CALL/CVS HEALTH/70/0.1/20.12.24 Share Price

Warrant

DE000VD324M0

Real-time Boerse Frankfurt Warrants 11:23:33 14/06/2024 pm IST
0.186 EUR -2.62% Intraday chart for BANK VONTOBEL/CALL/CVS HEALTH/70/0.1/20.12.24
Current month+14.81%
1 month+89.80%
Date Price Change
14/24/14 0.186 -2.62%
13/24/13 0.191 +9.14%
12/24/12 0.175 -6.91%
11/24/11 0.188 -2.59%
10/24/10 0.193 -16.09%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 11:23 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying CVS HEALTH CORPORATION
IssuerLogo Issuer Vontobel Vontobel
WKN VD324M
ISINDE000VD324M0
Date issued 12/04/2024
Strike 70 $
Maturity 20/12/2024 (187 Days)
Parity 10 : 1
Emission price 0.62
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.7
Lowest since issue 0.071
Spread 0.01
Spread %4.93%

Company Profile

CVS Health Corporation is one of the leading American suppliers of health products and services. Net sales (including intragroup) break down by activity as follows: - medical insurance plan management services (45.6%; Pharmacy Benefit Management): administrative management (reimbursement management, patient claim processing, etc.), drug distribution, decision-making information, sales of medical information management services, etc.; - retail distribution (28.5%): sale of prescription pharmaceutical products, OTC products, beauty and cosmetics products. At the end of 2023, products are marketed primarily via a network of more than 9,000 outlets and via the Internet. In addition, the group offers healthcare services through more than 1,000 clinics (MinuteClinic®); - medical benefits management (25.8%); - other (0.1%).
Sector
-
More about the company

Ratings for CVS Health Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: CVS Health Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
60.22 USD
Average target price
69.02 USD
Spread / Average Target
+14.61%
Consensus